Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Cash (2020 - 2025)

Historic Change in Cash for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$1.3 million.

  • Vivos Therapeutics' Change in Cash fell 12212.84% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year decrease of 16056.73%. This contributed to the annual value of $4.6 million for FY2024, which is 34610.87% up from last year.
  • As of Q3 2025, Vivos Therapeutics' Change in Cash stood at -$1.3 million, which was down 12212.84% from $2.1 million recorded in Q2 2025.
  • Vivos Therapeutics' Change in Cash's 5-year high stood at $20.1 million during Q2 2021, with a 5-year trough of -$6.2 million in Q1 2022.
  • Its 5-year average for Change in Cash is -$795736.8, with a median of -$3.0 million in 2023.
  • The largest annual percentage gain for Vivos Therapeutics' Change in Cash in the last 5 years was 646312.53% (2021), contrasted with its biggest fall of 104396.34% (2021).
  • Quarter analysis of 5 years shows Vivos Therapeutics' Change in Cash stood at -$4.5 million in 2021, then increased by 28.95% to -$3.2 million in 2022, then soared by 120.47% to $655000.0 in 2023, then crashed by 107.79% to -$51000.0 in 2024, then plummeted by 2478.43% to -$1.3 million in 2025.
  • Its Change in Cash stands at -$1.3 million for Q3 2025, versus $2.1 million for Q2 2025 and -$3.9 million for Q1 2025.